Lineage Cell Therapeutics Inc (LCTX) — Capital Reinvestment Ratio
Lineage Cell Therapeutics Inc (LCTX) has a Capital Reinvestment Ratio of 0.00x as of March 2022, meaning it reinvests 0% of its operating cash flow ($21.90 Million) in capital expenditures ($46.00K). Check Lineage Cell Therapeutics Inc (LCTX) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Lineage Cell Therapeutics Inc Capital Reinvestment Ratio (2022–2022)
This chart tracks Lineage Cell Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see Lineage Cell Therapeutics Inc (LCTX) cash flow conversion.
Annual Capital Reinvestment Ratio for Lineage Cell Therapeutics Inc (2022–2022)
Year-by-year Capital Reinvestment Ratio for Lineage Cell Therapeutics Inc from 2022 to 2022. See Lineage Cell Therapeutics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 0.39x | $1.06 Million | $413.00K | — |